Related Experiment Videos
Clinical trials and treatment prospects
1University of Alabama at Birmingham, School of Medicine, Birmingham, Alabama 35233, USA. apercy@peds.uab.edu
Summary
Rett syndrome (RS) research focuses on MECP2 gene mutations. Previous trials with L-carnitine, ketogenic diet, and naltrexone showed no significant improvements for Rett syndrome patients.
Area of Science:
- Neuroscience
- Genetics
- Pediatrics
Background:
- Rett syndrome (RS) is a neurodevelopmental disorder.
- Mutations in the methyl-CpG-binding protein 2 (MECP2) gene are found in over 80% of RS cases.
- Understanding MECP2 mutations offers therapeutic intervention prospects.
Purpose of the Study:
- Review previous clinical trials for Rett syndrome.
- Describe current clinical management strategies for RS medical issues.
- Preview an ongoing clinical trial for Rett syndrome.
Main Methods:
- Analysis of previous clinical trials (L-carnitine, ketogenic diet, naltrexone).
- Review of clinical management recommendations for RS symptoms.
- Description of an ongoing trial using folate and betaine supplementation.
Main Results:
- Previous RS trials with L-carnitine and naltrexone were double-blind, placebo-controlled, but showed no dramatic clinical improvements.
- Systematic evaluations for recommended clinical management strategies are lacking.
- An ongoing trial explores dietary supplementation (folate, betaine) for potential gene expression modulation.
Conclusions:
- Definitive therapeutic interventions for Rett syndrome are advancing due to MECP2 gene discovery.
- Controlled clinical trials require strict diagnostic criteria, stratification, and defined outcomes.
- Animal models of MECP2 mutations will aid future therapy evaluations for RS.